| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T84581 | ||||
| Target Name | Thioredoxin reductase, cytoplasmic | ||||
| Target Type | Successful |
||||
| Drug Potency against Target | 3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide | Drug Info | IC50 < 12500 nM | [530387] | |
| Bis(2,4-dinitrophenyl)sulfane | Drug Info | IC50 = 4000 nM | [528012] | ||
| 4,6-dinitrobenzo[c][1,2,5]thiadiazole | Drug Info | IC50 = 2000 nM | [528012] | ||
| References | |||||
| Ref 530387 | J Med Chem. 2009 Oct 22;52(20):6474-83.Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. | ||||
| Ref 528012 | Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92. Epub 2006 Feb 3.Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. | ||||
| Ref 528012 | Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92. Epub 2006 Feb 3.Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.